Acne Medication Market by Therapeutic Class, Formulation, Type, Acne Type, and Distribution Channel - Global Opportunity Analysis and Industry Forecast, 2017-2025

  • ID: 4580645
  • Report
  • Region: Global
  • 290 pages
  • Allied Analytics LLP
1 of 4
Acne or acne vulgaris is a skin disease caused due to clogging of hair follicles with dead skin cells and oil from skin cells. This disease is characterized with pimples, blackheads, oily skin, and scarring. There are two types of acne-non-inflammatory and inflammatory acne, where the latter takes longer duration to heal and can cause permanent effects on the skin. Acne medications are either applied directly, which are present in formulations, or taken in the form of oral pills. These medications work by reducing inflammation and oil production. They also fight with bacteria finally preventing scarring. The common acne medications include retinoids, antibiotics, isotretinoin, benzoyl peroxide, and others.

The global acne medication market was valued at $8,017 million in 2017, and is projected to reach $10,929 million by 2025 at a CAGR of 3.9% from 2018 to 2025. Increase in prevalence of acne diseases is the major factor that contributes toward the growth of the acne medication market. Moreover, other factors that fuel the market growth include unhealthy urban lifestyle, and presence of robust acne medications in pipeline. However, side-effects associated with the use of acne medications and presence of alternative treatment impede the market growth. Conversely, development of effective medications with lesser side effects and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market growth.

The global acne medication market is segmented into therapeutic class, formulation, type, acne type, distribution channel, and region. Based on therapeutic class, the market is divided into retinoids, antibiotics, salicylic acid, benzoyl peroxide, and others. The retinoids segment is further classified into topical retinoid & combination retinoid and oral retinoid (isotretinoin). The antibiotics segment is further sub-segmented into topical antibiotics & combination antibiotics and oral antibiotics. Based on the formulation, the market is bifurcated into topical medication and oral medication. Based on type, the market is categorized into prescription medicine and over-the-counter (OTC) medicine. By acne type, the market is divided into non-inflammatory and inflammatory acne. The distribution channel covered in the study include grocery store, pharmacy & drug store, and e-commerce. Based on region, it is analyzed for across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global acne medication market with current trends and future estimations from 2017 to 2025 to elucidate the imminent investment pockets.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

Key market segments

By Therapeutic Class

Retinoids
Topical Retinoid & Combination Retinoid
Oral Retinoid (Isotretinoin)
Antibiotics
Topical Antibiotic & Combination Antibiotics
Oral Antibiotics
Salicylic Acid
Benzoyl Peroxide
Others

By Formulation

Topical Medication
Oral Medication

By Type

Prescription Medicine
Over-the-counter (OTC) Medicine

By Acne Type

Inflammatory Acne
Non-inflammatory Acne

By Distribution Channel

Grocery Store
Pharmacy & Drug Store
e-Commerce

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Allergan Plc.
Nestle S.A.
Johnson & Johnson
Mayne Pharma Group Limited
Mylan N.V.
Pfizer Inc.
GlaxoSmithKline Plc
Sun Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Ltd.
Valeant Pharmaceuticals International, Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

Daiichi Sankyo Company, Ltd.
Ranbaxy Laboratories Limited
Medicis Pharmaceutical Corporation
Foamix Pharmaceuticals
Prestium Pharma, Inc.
BioPharmX, Inc.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. By Therapeutic Class
1.3.2. By Formulation
1.3.3. By Type
1.3.4. By Acne Type
1.3.5. By Distribution Channel
1.3.6. By Region
1.3.7. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Top player positioning, 2017
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of acne diseases
3.4.1.2. Unhealthy urban lifestyle
3.4.1.3. Rise in focus on skin care products
3.4.2. Restraints
3.4.2.1. Side effects associated with acne medications
3.4.2.2. Presence of alternatives for acne treatment
3.4.3. Opportunities
3.4.3.1. Opportunities in emerging economies
3.4.3.2. Development of therapeutics with lesser side effects
3.4.4. Impact analyses
3.5. Clinical trials
3.6. Patent analysis (2013-2018)
3.6.1. Patent analysis, by year
3.6.2. Patent analysis for China, by year

CHAPTER 4: ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Retinoid
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Topical & combination retinoid
4.2.2.1.1. Market size and forecast, by region
4.2.2.2. Oral retinoid (Isotretinoin)
4.2.2.2.1. Market size and forecast, by region
4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country
4.3. Antibiotics
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. Topical & combination antibiotics
4.3.2.1.1. Market size and forecast, by region
4.3.2.2. Oral antibiotics
4.3.2.2.1. Market size and forecast, by region
4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country
4.4. Salicylic acid
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Benzoyl Peroxide
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Other medications
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

CHAPTER 5: ACNE MEDICATION MARKET, BY FORMULATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Topical medications
5.2.1. Market size and forecast, by region
5.3. Oral medications
5.3.1. Market size and forecast, by region

CHAPTER 6: ACNE MEDICATION MARKET, BY TYPE
6.1. Overview
6.1.1. Market size and forecast
6.2. Prescription medicines
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Over-the-counter medicines
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

CHAPTER 7: ACNE MEDICATION MARKET, BY ACNE TYPE
7.1. Overview
7.1.1. Market size and forecast
7.2. Non-inflammatory acne
7.2.1. Market size and forecast, by region
7.2.2. Market analysis, by country
7.3. Inflammatory acne
7.3.1. Market size and forecast, by region
7.3.2. Market analysis, by country

CHAPTER 8: SOURCES: PRIMARY & SECONDARY RESEARCH AND AMR ANALYSIS ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL
8.1. Overview
8.1.1. Market size and forecast
8.2. Grocery store
8.2.1. Market size and forecast, by region
8.2.2. Market analysis, by country
8.3. Pharmacy & drug store
8.3.1. Market size and forecast, by region
8.3.2. Market analysis, by country
8.4. e-Commerce
8.4.1. Market size and forecast, by region
8.4.2. Market analysis, by country

CHAPTER 9: ACNE MEDICATION MARKET, BY REGION
9.1. Overview
9.1.1. Market size and forecast
9.2. North America
9.2.1. Key market trends, growth factors and opportunities
9.2.2. North America acne medication market, by country
9.2.2.1. U.S.
9.2.2.1.1. Market size and forecast, by therapeutic class
9.2.2.1.2. Market size and forecast, by type
9.2.2.1.3. Market size and forecast, by acne type
9.2.2.1.4. Market size and forecast, by distribution channel
9.2.2.2. Canada
9.2.2.2.1. Market size and forecast, by therapeutic class
9.2.2.2.2. Market size and forecast, by type
9.2.2.2.3. Market size and forecast, by acne type
9.2.2.2.4. Market size and forecast, by distribution channel
9.2.2.3. Mexico
9.2.2.3.1. Market size and forecast, by therapeutic class
9.2.2.3.2. Market size and forecast, by type
9.2.2.3.3. Market size and forecast, by acne type
9.2.2.3.4. Market size and forecast, by distribution channel
9.2.3. North America market size and forecast, by therapeutic class
9.2.4. North America market size and forecast, by formulation
9.2.5. North America market size and forecast, by type
9.2.6. North America market size and forecast, by acne type
9.2.7. North America market size and forecast, by distribution channel
9.3. Europe
9.3.1. Key market trends, growth factors and opportunities
9.3.2. Europe market size and forecast, by country
9.3.2.1. Germany
9.3.2.1.1. Market size and forecast, by therapeutic class
9.3.2.1.2. Market size and forecast, by type
9.3.2.1.3. Market size and forecast, by acne type
9.3.2.1.4. Market size and forecast, by distribution channel
9.3.2.2. France
9.3.2.2.1. Market size and forecast, by therapeutic class
9.3.2.2.2. Market size and forecast, by type
9.3.2.2.3. Market size and forecast, by acne type
9.3.2.2.4. Market size and forecast, by distribution channel
9.3.2.3. UK
9.3.2.3.1. Market size and forecast, by therapeutic class
9.3.2.3.2. Market size and forecast, by type
9.3.2.3.3. Market size and forecast, by acne type
9.3.2.3.4. Market size and forecast, by distribution channel
9.3.2.4. Italy
9.3.2.4.1. Market size and forecast, by therapeutic class
9.3.2.4.2. Market size and forecast, by type
9.3.2.4.3. Market size and forecast, by acne type
9.3.2.4.4. Market size and forecast, by distribution channel
9.3.2.5. Spain
9.3.2.5.1. Market size and forecast, by therapeutic class
9.3.2.5.2. Market size and forecast, by type
9.3.2.5.3. Market size and forecast, by acne type
9.3.2.5.4. Market size and forecast, by distribution channel
9.3.3. Rest of Europe
9.3.3.1.1. Market size and forecast, by therapeutic class
9.3.3.1.2. Market size and forecast, by type
9.3.3.1.3. Market size and forecast, by acne type
9.3.3.1.4. Market size and forecast, by distribution channel
9.3.4. Europe market size and forecast, by therapeutic class
9.3.5. Europe market size and forecast, by formulation
9.3.6. Europe market size and forecast, by type
9.3.7. Europe market size and forecast, by acne type
9.3.8. Europe market size and forecast, by distribution channel
9.4. Asia-Pacific
9.4.1. Key market trends, growth factors and opportunities
9.4.2. Asia-Pacific market size and forecast, by country
9.4.2.1. Japan
9.4.2.1.1. Market size and forecast, by therapeutic class
9.4.2.1.2. Market size and forecast, by type
9.4.2.1.3. Market size and forecast, by acne type
9.4.2.1.4. Market size and forecast, by distribution channel
9.4.2.2. China
9.4.2.2.1. Market size and forecast, by therapeutic class
9.4.2.2.2. Market size and forecast, by type
9.4.2.2.3. Market size and forecast, by acne type
9.4.2.2.4. Market size and forecast, by distribution channel
9.4.2.3. India
9.4.2.3.1. Market size and forecast, by therapeutic class
9.4.2.3.2. Market size and forecast, by type
9.4.2.3.3. Market size and forecast, by acne type
9.4.2.3.4. Market size and forecast, by distribution channel
9.4.2.4. Australia
9.4.2.4.1. Market size and forecast, by therapeutic class
9.4.2.4.2. Market size and forecast, by type
9.4.2.4.3. Market size and forecast, by acne type
9.4.2.4.4. Market size and forecast, by distribution channel
9.4.2.5. South Korea
9.4.2.5.1. Market size and forecast, by therapeutic class
9.4.2.5.2. Market size and forecast, by type
9.4.2.5.3. Market size and forecast, by acne type
9.4.2.5.4. Market size and forecast, by distribution channel
9.4.2.6. Rest of Asia-Pacific
9.4.2.6.1. Market size and forecast, by therapeutic class
9.4.2.6.2. Market size and forecast, by type
9.4.2.6.3. Market size and forecast, by acne type
9.4.2.6.4. Market size and forecast, by distribution channel
9.4.3. Asia-Pacific market size and forecast, by therapeutic class
9.4.4. Asia-Pacific market size and forecast, by formulation
9.4.5. Asia-Pacific market size and forecast, by type
9.4.6. Asia-Pacific market size and forecast, by acne type
9.4.7. Asia-Pacific market size and forecast, by distribution channel
9.5. LAMEA
9.5.1. Key market trends, growth factors and opportunities
9.5.2. LAMEA market size and forecast, by country
9.5.2.1. Brazil
9.5.2.1.1. Market size and forecast, by therapeutic class
9.5.2.1.2. Market size and forecast, by type
9.5.2.1.3. Market size and forecast, by acne type
9.5.2.1.4. Market size and forecast, by distribution channel
9.5.2.2. Saudi Arabia
9.5.2.2.1. Market size and forecast, by therapeutic class
9.5.2.2.2. Market size and forecast, by type
9.5.2.2.3. Market size and forecast, by acne type
9.5.2.2.4. Market size and forecast, by distribution channel
9.5.2.3. South Africa
9.5.2.3.1. Market size and forecast, by therapeutic class
9.5.2.3.2. Market size and forecast, by type
9.5.2.3.3. Market size and forecast, by acne type
9.5.2.3.4. Market size and forecast, by distribution channel
9.5.2.4. Rest of LAMEA
9.5.2.4.1. Market size and forecast, by therapeutic class
9.5.2.4.2. Market size and forecast, by type
9.5.2.4.3. Market size and forecast, by acne type
9.5.2.4.4. Market size and forecast, by distribution channel
9.5.3. LAMEA market size and forecast, by therapeutic class
9.5.4. LAMEA market size and forecast, by formulation
9.5.5. LAMEA market size and forecast, by type
9.5.6. LAMEA market size and forecast, by acne type
9.5.7. LAMEA market size and forecast, by distribution channel

CHAPTER 10: COMPANY PROFILES
10.1. Allergan Plc
10.1.1. Company overview
10.1.2. Company snapshot
10.1.3. Operating business segments
10.1.4. Product portfolio
10.1.5. Business performance
10.1.6. Key strategic moves and developments
10.2. Nestle S.A. (Galderma S.A.)
10.2.1. Company overview
10.2.2. Company snapshot
10.2.3. Operating business segments
10.2.4. Product portfolio
10.2.5. Business performance
10.2.6. Key strategic moves and developments
10.3. Johnson & Johnson
10.3.1. Company overview
10.3.2. Company snapshot
10.3.3. Operating business segments
10.3.4. Product portfolio
10.3.5. Business performance
10.4. Mayne Pharma Group Limited
10.4.1. Company overview
10.4.2. Company snapshot
10.4.3. Operating business segments
10.4.4. Product portfolio
10.4.5. Business performance
10.4.6. Key strategic moves and developments
10.5. Mylan N.V.
10.5.1. Company overview
10.5.2. Company snapshot
10.5.3. Operating business segments
10.5.4. Product portfolio
10.5.5. Business performance
10.6. Pfizer Inc.
10.6.1. Company overview
10.6.2. Company snapshot
10.6.3. Operating business segments
10.6.4. Product portfolio
10.6.5. Business performance
10.7. GlaxoSmithKline Plc (Stiefel Laboratories, Inc.)
10.7.1. Company overview
10.7.2. Company snapshot
10.7.3. Operating business segments
10.7.4. Product portfolio
10.7.5. Business performance
10.8. Sun Pharmaceutical Industries Limited
10.8.1. Company overview
10.8.2. Company snapshot
10.8.3. Operating business segments
10.8.4. Product portfolio
10.8.5. Business performance
10.8.6. Key strategic moves and developments
10.9. Teva Pharmaceutical Industries Ltd.
10.9.1. Company overview
10.9.2. Company snapshot
10.9.3. Operating business segments
10.9.4. Product portfolio
10.9.5. Business performance
10.9.6. Key strategic moves and developments
10.10. Valeant Pharmaceuticals International, Inc.
10.10.1. Company overview
10.10.2. Company snapshot
10.10.3. Operating business segments
10.10.4. Product portfolio
10.10.5. Business performance
10.10.6. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to a new report titled, Acne Medication Market, by Therapeutic Class, Formulation, Type, Acne Type, and Distribution Channellobal Opportunity Analysis and Industry Forecast, 2018-2025," the global acne medication market was valued at $8,017 million in 2017, and is projected to reach $10,929 million by 2025, registering a CAGR of 3.9% from 2018 to 2025.

Acne is a long-term skin disease that appears because of clogged hair follicles, dead skin cells, and oil excreted from skin. It is characterized by the presence of considerable number of pimples, whiteheads, blackheads, oily skin, and probable scarring. It generally affects the skin with comparatively high number of sweat glands at upper part of chest, back, and face. Acne medications are drugs that are indicated for the treatment of acne. These include several prescription and over-the-counter medicines such as retinoids, isotretinoin, antibiotics, salicylic acid, benzoyl peroxide, oral contraceptives, and others.

The factors that drive the growth of the acne medication market include increase in prevalence of acne vulgaris across the world, unhealthy urban lifestyle, surge in pollution, and rise in focus on skin care products. However, side effects associated with acne medications and reforms, and presence of alternative treatment options such as laser therapies, impede the market growth. Conversely, the development of newer products with lesser side effects and presence of untapped market in the emerging economies are expected to provide lucrative growth opportunities for the market.

The retinoids segment accounted for the largest share in 2017, owing to high usage in treatment of acne and lesser side effects as compared to other therapeutics. However, the salicylic acid segment is expected to grow at the high CAGR from 2018 to 2025.

The inflammatory acne segment is the largest acne type segment in the global acne medication market in 2017 and is expected to maintain its lead in the forecast period. On the other hand, non-inflammatory acne segment is anticipated to record the highest CAGR from 2018-2025.

By type, the prescription medicine segment dominated the global acne treatment market in terms of revenue in 2017 and the trend is projected to continue throughout the forecast period.

The utilization rate of topical medications for acne treatment is high owing to high availability of these products with high success rate and lesser side effects. However, the oral medication segment is expected to grow at a CAGR of 3.6% during the forecast period.

Key Findings of the Acne Medication Market

The antibiotics segment accounted for nearly one-fourth share of the global acne medication market in 2017.
The over-the-counter medicine segment is expected to grow at a CAGR of 2.9% from 2018 to 2025.
The non-inflammatory acne segment accounted for around two-fifths share of the global market in 2017.
Europe accounted for around one-fourth share of the global market in 2017.
LAMEA is expected to provide lucrative market growth opportunities and grows with the CAGR of 4.5% from 2018 to 2025.

North America was the leading revenue contributor to the global acne medication market in 2017, and is expected to dominate the market during the forecast period. This is attributed to the early approval of acne medication products and high adoption of prescription medicines in this region. However, Asia-Pacific is expected to grow at the highest CAGR of 5.6% during the study period, due to increase in affordability, surge in healthcare expenditure, and rise in awareness toward safe acne medications products.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll